Are Psychedelics Addictive in Australia? A Guide to the Evidence

Psychedelics have captured global attention for their potential to treat mental health conditions. In Australia, the legal landscape for substances like psilocybin and MDMA has evolved dramatically since 2023. Nevertheless, a common question remains: are psychedelics addictive? This guide explores the evidence on psychedelic addiction, focusing on the Australian context, including clinical trials, community use, and harm reduction.

Understanding Addiction and Psychedelics

Addiction is a complex condition characterized by compulsive drug seeking and use despite harmful consequences. It involves changes in brain chemistry and behavior. Psychedelics like psilocybin, LSD, and MDMA have different pharmacological profiles compared to substances like opioids or stimulants. Consequently, their addiction potential differs significantly.

Psilocybin and Classic Psychedelics

The evidence suggests that psilocybin has a low potential for addiction and dependence. The TGA, in its decision to reschedule psilocybin, acknowledged that “the risk of addiction is low in a highly controlled environment for psilocybin assisted therapy” . Furthermore, the TGA noted that “psilocybin does not produce dependency at its established therapeutic dose” and that patients only have 2-3 sessions with the medicine, never taking it home .

Australian data supports this view. The National Drug & Alcohol Research Centre (NDARC) reported no overdose, misuse, or abuse of psilocybin between 2000 and 2019 . Additionally, the Australian Bureau of Statistics has never reported on psilocybin misuse or abuse . The mechanism of action also reduces abuse potential. Psilocybin produces significant tolerance buildup, meaning repeat and multiple dosing becomes ineffective, making abuse potential even in recreational environments low .

However, this does not mean psilocybin is without risk. Calls to the NSW Poisons Information Centre regarding psilocybin more than doubled from 2014 to 2022 . Most of these calls (85%) were from or referred to hospital, and co-ingestion with other substances occurred in a third of cases . The primary risks are psychological, including challenging experiences (“bad trips”), anxiety, and in rare cases, self-harm .

MDMA (Ecstasy)

MDMA presents a different picture. A major Australian longitudinal study from Victoria found that MDMA use in early adulthood was associated with increased odds of anxiety disorders by the mid-30s . The study found that frequent MDMA use was linked to 2.56 times the odds of an anxiety disorder compared to non-users . However, MDMA use was not linked to depressive disorders . This suggests that while MDMA may not create classical physical dependence, it carries significant long-term mental health risks.

Public health warnings from NSW Health highlight the risks of high-dose MDMA, which has been linked to death and serious harms . Unregulated MDMA can vary significantly in purity and dose, increasing the risk of adverse events.

Australian Clinical Trials and Safety

Clinical trials in Australia provide crucial safety data. A pilot study at St. Vincent’s Hospital, Sydney, investigated psilocybin-assisted psychotherapy for methamphetamine use disorder. No serious adverse events occurred, and the seven treatment-related adverse events were self-limiting and mild to moderate . Notably, participants in this study reported reduced methamphetamine use and craving following psilocybin treatment . Qualitative interviews revealed that participants’ psychedelic experiences often led to new understandings of themselves and reduced salience of methamphetamine use . These findings suggest that psilocybin may even be a potential treatment for addiction.

Community Use and Harm Reduction

Psychedelic use in naturalistic settings in Australia is increasing, with psilocybin use doubling between 2019 and 2023 . Consequently, harm reduction strategies are becoming increasingly important. Users employ various strategies, including knowledge seeking, preparation of mindset and setting, and social support . However, the review identified challenges, such as low uptake of drug checking services and low trust in government institutions .

Australian Government policy supports harm reduction as the third pillar of its drug strategy . Unlike clinical trials, community use carries greater risks due to uncontrolled settings, variable dosage, and potential poly-drug use.

Conclusion

The evidence from Australia indicates that classic psychedelics like psilocybin have a low potential for addiction and physical dependence, a view supported by the TGA. MDMA, however, is associated with a significantly increased risk of anxiety disorders but not depression. Both substances carry substantial psychological risks, particularly when used outside controlled clinical settings. Australian clinical trials are expanding the understanding of these substances, offering hope for new treatments, but community use remains a concern for public health. For those seeking psychedelic therapies, the only safe and legal path is through authorised psychiatrists in a regulated environment.